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Summary
Through their effects on the intestinal epithelium and immunity, gut microbes and their 
fermentative byproducts can influence metabolic and psychological health parameters in patients 
with AN. Integrative therapies that restore gut microbial health may also benefit individuals with 
conditions in which gut microbial dysbiosis manifests, as in T1D, as individuals in this population 
experience difficulties with weight stabilization and altered metabolic traits and are vulnerable to 
developing symptoms of disordered eating.
Although the clinical implications of the brain-gut-microbiota axis are not yet fully understood in 
AN, targeted pro- and antibiotics represent two mechanisms by which augmenting the gut 
microbiota can serve as an ancillary therapy for lessening severity of bloating and discomfort 
during treatment. Specifically, antibiotics could be used to eliminate known pathogens that disrupt 
intestinal integrity, while targeted probiotics may help to restore beneficial species known to 
promote gut epithelial health. Thus, we conclude that controlled studies investigating use of such 
novel therapies, including FMT, should be undertaken as part of an interdisciplinary approach to 
address metabolic and psychological factors that influence acute and long-term health outcomes in 
AN and T1D. We highlight again that work on the role of the intestinal microbiota in eating 
disorders is both limited and confined to AN. As is commonly the case, biological research in 
eating disorders starts with AN before progressing to the other eating disorders presentations. Yet, 
in many ways, eating disorders are model conditions on in which to explore the gut-brain axis 
given the centrality of eating and metabolic factors to the illnesses. We encourage investigators to 
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expand on this early work by conducting studies on the other eating disorders (both in youth and 
adults) to develop a more comprehensive picture of the role that the intestinal microbiota plays in 
the development and maintenance of and recovery from these debilitating illnesses.
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Introduction
The three most common eating disorders are anorexia nervosa (AN), bulimia nervosa (BN), 
and binge-eating disorder (BED). Other presentations such as avoidant and restrictive food 
intake disorder (AFRID), purging disorder (PD), and night eating syndrome (NES) also exist 
and can be debilitating, yet we know virtually nothing about the role of the intestinal 
microbiota in these disorders. In fact, of the primary eating disorders, our understanding of 
the intestinal microbiota is limited to research on AN, which is the focus of this review. 
According to the Diagnostic Statistical Manual of Mental Disorders, 5th edition (DSM-5), 
AN is characterized by three diagnostic criteria:
1. restriction of energy intake relative to requirements leading to significantly low 
body weight,
2. fear of weight gain or becoming fat, or persistent behaviors to avoid weight gain 
despite low weight, and
3. disturbances in self-perceived weight and shape or persistent lack of recognition 
of the seriousness of the low weight.
Two subtypes—restricting AN (AN-R) and AN binge-purge (AN-BP) exist. Individuals with 
AN-R reach dangerous low weights primarily through restriction of food intake and/or 
excessive exercise or physical activity. Those with AN-BP also experience episodes of binge 
eating and/or purging as typical of BN.
Prevalence and etiology
The lifetime prevalence of AN has been reported to be between 1 and 4% of the population 
and the illness disproportionately affects women3. One 2007 case-control study from a 
cohort of Finnish women determined that the lifetime prevalence of AN according to DSM-
IV criteria was 2.2%, which was higher than in previous studies that had ascertained cases of 
AN on the basis of hospital records alone3. Indeed, only about one-third of patients with 
eating disorders are ever detected by the healthcare system3, demonstrating the importance 
of clarifying ascertainment strategy when discussing prevalence of eating disorders.
Furthermore, the new, expanded criteria for a diagnosis of AN in DSM-5 have necessitated a 
recalculation of prevalence. A Japanese study reported that the prevalence of lifetime AN 
increased by 60% in the transition to DSM-5, with evidence of somewhat lower severity 
associated with the DSM-5 cases4. A US study of 391 predominantly Caucasian (76.5%) 
female (91%) participants reported a jump from 14% (DSM-IV) to 20% (DSM-5) percent of 
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participants classified as having AN5. Although compelling, the results of both studies 
should be interpreted with caution as they are much higher than other estimates. A 2.5% 
increase in AN prevalence was reported in the shift from DSM-IV to DSM-5 criteria in a 
Portuguese sample of female high school and university students6. While the increased 
flexibility of the new criteria are favorable for insurance reimbursement in that they will 
allow a greater number of individuals to be treated, those who are classified as having AN 
may now present as a more heterogeneous group in terms of severity and metabolic 
phenotype, and should therefore be evaluated at the individual level when considering novel 
therapies such as those that will be discussed in this review.
In terms of risk for developing AN, both genetic and environmental factors are implicated7. 
Indeed, replicated twin studies have estimated the heritability of AN to be around 50–60%8. 
Results from a recent genome-wide association study (GWAS) suggest both psychiatric and 
metabolic etiological factors9. Thus, advances in AN treatment may need to focus not only 
on psychiatric, but also metabolic factors.
Treatment and prognosis
Current treatments for AN are often ineffective or lead to partial recovery, with frequent 
relapse, especially among adults10,11. Adolescents generally fare better, although relapse 
following full recovery occurs in between 7.1% and 21% of patients12–14. Further, relapse 
has been defined inconsistently, and follow-up lengths and treatment modalities have varied. 
With respect to recovery rate, one study estimated that 66.8% of patients maintained normal 
weight and menstrual cycle while abstaining from binge-eating and purging behaviors for a 
minimum of one year post-treatment15.
Therapeutic renourishment remains the cornerstone of the treatment of AN. A review 
describing developments in the treatment of AN recognized family based therapy (FBT) as 
being beneficial for youth, whereas for adults, a number of psychological approaches 
including cognitive behavioral therapy (CBT), specialist supportive clinical management, 
and interpersonal psychotherapy (IPT) have been recommended16. No medications have 
been found to be effective in the treatment of AN11.
AN remains the deadliest of any psychiatric illness. A systematic review calculated weighted 
annual mortality for AN as 5.10 deaths (95% CI, 3.99–6.14) per 1000 person-years, of 
which 1.3 deaths were attributed to suicide17. In a subsequent study, suicide was verified as 
a leading cause of death among individuals with AN18. Other factors contributing to high 
mortality rates in AN include susceptibility to infection, dehydration, and electrolyte 
imbalance19. This highlights a pressing need for novel safe and effective treatments for AN.
Gut microbial health influences psychology and behavior
Multiple biologically plausible pathways have been proposed to explain the relationship 
between intestinal microbiota and neurological processes, including microbial production 
and modulation of neurotransmitters, short-chain fatty acids (SCFA), brain-derived 
neurotrophic factor (a protein with signaling properties in the central nervous system and 
periphery), inflammation, and the hypothalamic-pituitary axis (implicated in depression 
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through secretion of hormones that stimulate cortisol production)20. A growing body of 
research—in both animals and humans—supports the concept of a brain-gut-microbiota 
axis21–25, whose signals to physiologic and neurologic processes include those related to 
eating behavior and mood.
Associations between gut microbiota and AN
Alterations in gut microbial composition and diversity
Gut microbial diversity varies inversely with severity of disease states, including in AN26 
and T1D27,28, among others. This is especially true when comparing patients with AN pre- 
and post-treatment and to normal weight (NW) healthy controls26,29. Interestingly, reduced 
enteric microbial diversity has been associated with higher depression in AN29. The link 
between gut microbial dysbiosis and depression in AN could be an important one, as a 
diagnosis of major depressive disorder was found to be a predictor of long-term AN-R 
persistence in one study (OR 5.87, P=0.01)30.
The caloric restriction characteristic of AN invites speculation that this illness allows 
microorganisms capable of surviving in a calorie-poor environment to thrive31. For instance, 
multiple studies suggest that the methane-producing archeon Methanobrevibacter smithii is 
more abundant in AN26,32,33. This increased abundance may represent an adaptive response 
to very low energy intake. Indeed, M. smithii metabolizes the hydrogen produced during 
bacterial fermentation, preventing the build- up of hydrogen gas and allowing increased 
transformation of nutrients into calories32,33, which may benefit the host during nutrient-
limited conditions. In addition, a significant decrease in the abundance of the phylum 
Bacteroidetes was reported among AN patients at baseline compared with NW controls, 
which persisted following weight restoration (FDR-adjusted P < 0.15 at baseline and P < 
0.05 at follow-up)26. On the other hand, the phylum Firmicutes was significantly elevated in 
post-treated AN patients, but not at baseline, compared to NW controls (FDR-adjusted P < 
0.05). Another bacterial phylum, Actinobacteria, was significantly elevated in AN patients 
relative to controls prior to and following weight restoration (FDR-adjusted P < 0.05 for 
both). Ultimately, there is little consistency as to which microbial phyla are associated with 
AN before or after clinical refeeding, most likely due to differing regional populations and 
treatment regimes.
Notably, Mack et al. found that relative abundance of several mucin degraders— whose 
activities may be pathological for the gut epithelium—was increased among AN patients 
compared to healthy controls at baseline (FDR-adjusted P < 0.15 for Verrucombia in AN 
group vs. controls). However, this difference was no longer statistically significant following 
treatment26. The difference in abundance of mucindegraders was also significantly reduced 
from baseline to follow-up among AN patients (FDR-adjusted P < 0.05 for Verrucombia)26, 
suggesting that certain gut microbial changes may serve as benchmarks for recovery. (Figure 
1)
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Delayed gastrointestinal motility
Methane production by M. smithii can contribute to constipation and slowed gastrointestinal 
motility, allowing more time for energy harvest from the diet32,34. This theory derives 
further support from studies demonstrating positive associations between M. smithii counts 
and either BMI or weight gain32,35,36, as well as associations between breath methane and 
high BMI34,37,38. As mentioned previously, the abundance of this archeon is elevated in AN 
patients, although research is needed to clarify the role of M. smithii in influencing energy 
metabolism and weight status among individuals with or without this illness. Arguably, M. 
smithii might be an ally in weight restoration, insofar as it allows for increased fermentation 
of carbohydrates to SCFAs that can provide energy to the host. However, SCFA are likely 
not a significant source of energy, as fermentation of 32 to 42 grams of indigestible 
carbohydrate would produce SCFA equivalent to only two to four percent of daily energy 
needs39. M. smithii might also compete for utilization of SCFAs, thereby limiting any 
potential benefit. Moreover, as M. smithii contributes to slowed intestinal motility and 
constipation, it may discourage food intake and thereby interfere with weight restoration.
Kamal et al. verified that intestinal motility, or gastric transit time is delayed among AN 
patients by measuring whole-gut and mouth to cecum transit time. As hypothesized, whole-
gut transit time was significantly delayed among AN patients compared with healthy 
controls (P < 0.05), while mouth to cecum transit time also trended towards being increased, 
although the difference did not reach statistical significance40.
Implications for treatment
Delayed gastric transit time has been reported to elevate colonization of the gut by slow-
growing mucin-degrading microbes, which may conceivably promote AN- associated 
bloating41. Moreover, patients may increase fiber consumption to relieve constipation-
associated bloating, which can further exacerbate symptoms via gaseous byproducts of 
microbial fermentation42. Bloating symptoms may then disincentivize recovery and intensify 
fear of weight gain, although these byproducts of treatment can be circumvented through use 
of antibiotics. For instance, elimination of M. smithii using antibiotic rifaxamin has been 
shown to reduce bloating symptoms43, while other probiotics have relieved bloating 
symptoms in trials of functional bowel disorders44. However, their influence on indigenous 
mucin-degrading microbes remains unknown.
Intestinal permeability, autoimmunity, and effects on appetite
Alterations in gut permeability have been demonstrated in both human and mouse models of 
AN45. This may allow foreign invaders to activate the immune system and stimulate the 
production of autoantibodies that target neuropeptides, including anorexigenic (appetite-
suppressing) α-melanocyte-stimulating hormone (α-MSH) and orexigenic (appetite-
stimulating) ghrelin46–48. This particular phenomenon has been observed in healthy women 
and rats47.
In support of the concept that autoimmunity contributes to ED, Terashi et al. have speculated 
that changes in abundance and binding availability of ghrelin autoantibodies contribute to 
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the elevated plasma ghrelin and ghrelin resistance characteristic of AN49,50. Additionally, 
autoantibodies to α-MSH were found in most AN patients and a positive correlation 
between autoantibody levels and ED pathology was detected51,52. In rodents, α-MSH 
autoantibodies were induced by caseinolytic protease B (ClpB) – an enzyme produced by 
Enterobacteriaceae, microbes observed at higher concentrations in AN patients by multiple 
research groups33,53,54. Associations between ClpB concentration and psychopathological 
traits have also been detected in AN patients53.
In contrast to other findings, reduced small intestinal permeability has also been reported 
among patients with AN55. It is possible that the effects of AN on intestinal permeability are 
site-specific; arguably, differential effects on the small intestine and the colon may reflect 
the role of gut microbiota in regulating permeability, as the highest concentrations of 
microbes occur in the colon44,56. At the same time, as Jésus et al.45 used a mouse model, 
their findings may not translate to humans. Moreover, the level of caloric restriction in these 
mice—typically 30 to 40 percent of total calories—may not match the level of caloric 
restriction common in individuals with AN, which itself is difficult to measure accurately.
Excessive exercise alters intestinal permeability and gut microbial composition
Exercise intensity and intestinal permeability are positively correlated57,58. The activity-
based anorexia (ABA) mouse phenotype yields hyperactivity via limited access to food. 
Increased colonic permeability and altered tight junction protein expression have been 
demonstrated in ABA mice45. Higher levels of mucin-degrading Akkermansia muciniphila 
have also been observed in athletes. The investigators speculated that A. muciniphila may 
improve barrier function by mechanisms still not fully understood, whereas others 
hypothesized that increased levels of the microbe would compromise the mucus layer of the 
epithelium and thereby the integrity of the intestinal barrier59,60.
Studies of forced activity in rodents could reveal how excessive exercise could affect the gut 
microbiota in AN, as it may better approximate the compulsive, compensatory exercise 
associated with AN rather than voluntary exercise. For example, Allen et al. found that mice 
subjected to forced treadmill running (FTR) had greater microbial diversity and altered gut 
microbial composition relative to mice exposed to voluntary wheel running61. While 
increased gut microbial diversity is generally associated with better health, here it was 
related to an expansion of rare bacterial species. The FTR mouse feces also exhibited a 
predominance of taxa that have been linked to disease states.
SCFA
Role in human health
SCFA—dietary metabolites produced by gut microbial fermentation of indigestible dietary 
carbohydrates—are an emerging topic of interest in metabolic health and weight 
management. Butyrate is a widely studied SCFA that is known to stimulate goblet cell 
mucin synthesis, which promotes gut health by lubricating and protecting epithelial cells. 
Butyrate also serves as a salient energy source for the intestinal epithelium62. Interestingly, 
butyrate is primarily found in milk fat63. SCFA production could be reduced in AN due to 
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avoidance of fat-containing food products (13% of calories consumed from fat have been 
noted in AN patients vs. 31% in controls)64.
Fecal SCFA are reduced in AN
Most studies have reported reduced fecal SCFA in AN patients compared with controls. 
Borgo et al. detected significantly lower fecal concentrations of total SCFA (P = .041), 
butyrate (P = .045), and propionate (P = .028); notably, their finding of decreased butyrate is 
consistent with decreased carbohydrate-fermenting genera Ruminococcus (p = .019), 
Roseburia (P = .037), and Clostridium (P = .031)33. Decreased acetate (P = .0003) and 
propionate (P = .001) were found in AN patients in Japan compared to healthy controls65. 
By contrast, Mack et al.26 reported comparable fecal concentrations of total SCFA, acetate, 
butyrate, and propionate in AN patients and controls. They nevertheless detected reduced 
butyrate as a percentage of total SCFA among AN patients on admission, compared with 
discharge and with normal weight controls, which concurred with a reduced abundance of 
butyrate-producing Roseburia. Further, butyrate concentration correlated with Roseburia 
abundance in all three groups. The inconsistencies across studies may reflect compositional 
differences that occur across geographical regions66,67.
To remedy reduced SCFA production in AN patients, some have proposed administering 
butyrate-producing Roseburia or supplementing directly with SCFAs26,68. Theoretically, 
increased intake of carbohydrates and prebiotic fibers would also enhance SCFA production. 
However, the bacterial fermentation of carbohydrates would also contribute to gas, bloating, 
and distention, producing physical discomfort after meals and potentially exacerbating body 
image concerns.
Parallels between AN and T1D
Energy dysregulation
Alterations in energy metabolism are central to both T1D and AN. Similar to the catabolic 
state that occurs due to starvation in AN69, severe weight loss is a feature of untreated 
T1D69,70. Even when treated, elevated resting energy expenditure (REE) has occurs in 
individuals with T1D relative to prediction equations for healthy individuals71,72. Although 
reduced REE occurs in underweight AN73, many patients experience hypermetabolism 
during refeeding for unknown reasons74.
Etiology, prevalence, and complications of disordered eating in T1D
It is tempting to speculate that the increased prevalence of disordered eating among 
individuals with T1D is a function of constant carbohydrate counting for blood glucose 
control and intense attention to weight. Although this behavior is initially medically-driven, 
food restriction, defined as restraint, or self-imposed resistance to food consumption75, is 
associated with undesirable shifts in behavior and metabolism. One such behavior includes 
insulin restriction76, which can lead to uncontrolled blood glucose77,78 and thus acute and 
chronic health complications. Schober et al. found that reasons most commonly reported for 
insulin omission included denial of the disease in situations with peers (30%), self-
destructive behavior and suicidal ideation (28%), fear of severe hypoglycemia (24%), and 
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intention to lose weight (15.5.%)79. Conversely, intentional insulin overdosing to enable 
binge eating has also been commonly reported among individuals with T1DM79. Elevated 
BMI may also result, as restraint can lead to uncontrolled overeating when individuals cease 
to limit their food intake80,81.
Furthermore, co-occurring T1D and ED may interact to synergistically worsen health 
outcomes. In one study, mortality via diabetes-related metabolic complications was 
increased with co-occurring T1D and AN, compared with either disorder alone 
(standardized mortality ratio 4.06, 8.86, and 14.5 for T1D, AN, and T1D and AN combined, 
respectively)82. Peveler et al. reported that among individuals with T1D, those with EDs had 
a higher baseline Hemoglobin A1c (HbA1c – a three-month measure of BG) than those 
without an ED (11.9 vs. 9.4 , P = 0.009)78. However, HbA1c was not associated with ED 
status at 8 to 12 year follow-up points, suggesting that in some instances, disordered eating 
behaviors may normalize following adolescence78.
A systematic review suggests that both BN and the combined presence of BN and AN are 
significantly elevated in patients with T1D compared with controls (both P < 0.05)2. Of 550 
female patients with T1D, 1% had lifetime AN and 16.2% had lifetime BN83. Subthreshold 
disordered eating is also prevalent, with one study reporting a greater proportion of girls 
aged 9–14 with T1D reporting two or more unhealthy eating behaviors compared to non-
diabetic controls (P < 0.0005)84.
Gut microbial dysbiosis in T1D
Although shifts in dietary behaviors rapidly and reliably alter the enteric microbial 
community, much of the literature linking T1D with changes in the gut microbiota has 
focused on infants and children proximal to T1D onset. Most27,28, but not all85 studies 
report reduced enteric microbial diversity among patients who develop autoimmunity to 
pancreatic islet cells compared to controls. Compositional differences were reported in two 
independent cohorts of Mexican and Finnish children displaying increased Bacteroides 
among T1D cases and Prevotella among controls86,87. Another research team found that two 
species from the Bacteroides phylum were significantly increased among Finnish T1D case 
children months before diabetes onset88. Yet other studies reported reduced abundance of 
Bifidobacterium in patients compared with controls89,90, although other compositional 
differences have been less consistently observed27,85,89.
Similar to AN, reduced fecal SCFA have been observed among individuals with T1D 
compared to controls. Despite a trend towards increased fiber consumption among 
individuals with T1D compared to non-diabetic controls in one study, control participants 
had increased levels of plasma acetate and propionate compared to the T1D group, although 
total fecal SCFA were similar91. This may suggest enhanced utilization of SCFA metabolites 
by individuals with T1D before they reach the plasma, perhaps in order to fulfill functions 
related to gut epithelial integrity.
The gut microbiota is associated with weight status and glycemia
It is important to note that gut microbial composition has also been found to shift reliably in 
association with changes in weight status and metabolic parameters— including glucose 
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homeostasis—in both animal and human models, which is relevant considering the increased 
prevalence of overweight and obesity among individuals with T1D92. For instance, Rabot et 
al. showed that germ-free mice fed a high-fat diet were able to maintain euglycemia (normal 
blood glucose), although conventionally-raised mice with gut microbiota that had been 
allowed to colonize naturally, developed glucose intolerance and had higher plasma insulin 
concentrations in both a fed and 6-hour unfed state93. In a study with human participants, 
Nadal et al. found that changes in blood glucose significantly correlated with changes in 
proportions of gut microbial groups in adolescents participating in a weight loss 
intervention, regardless of weight loss outcome (P=0.006)94. Of note, diagnostic crossover is 
common in eating disorders, meaning that during the course of an individual’s illness, they 
may transition across diagnostic presentations (AN, BN, BED)95, which can entail 
considerable fluctuations in weight. No work has yet been done to understand how the gut 
microbiota may be implicated in these longitudinal changes in symptom presentation.
Genetics
The association between AN and T1D may reflect shared genetic variants, including those 
related to metabolism. An AN GWAS detected one genome-wide significant variant for 
AN9, which was previously found to be associated with T1D. Significant genetic 
correlations emerged between AN and multiple metabolic traits implicated in T1D, 
including insulin resistance, fasting insulin, fasting glucose, and cholesterol and lipid 
measures9. These findings are consistent with evidence of increased ED prevalence and 
disordered eating among individuals with T1D, as well as increased risk of autoimmune 
disorders, especially of endocrinological and gastroenterological types, among individuals 
with ED48. Considerably more work is essential to confirm and dissect the nature of this 
relationship. Larger sample sizes for AN GWAS are critical first steps for any more detailed 
analysis of the association.
Future directions
It is vital to consider genetic, metabolic, and psychological factors that influence AN and 
multifactorial disorders such as T1D, in which symptoms of disordered eating, energy 
dysregulation, gut microbial dysbiosis manifest. Fecal microbiota transplantation (FMT), or 
the transfer of fecal microbiota from healthy donors to diseased patients, is one potential 
treatment that is on the horizon for many disease states including T1D and AN96 based on 
its effectiveness at treating Clostridium difficile infections97. One challenge with respect to 
translational application of FMT to other disease states is donor screening, as systematic 
assessments of donor health have yet to be established. Furthermore, no standard exists for 
ideal gut microbial composition, although screening out individuals with pathogenic gut 
microorganisms is critical. However, preliminary evidence exists that FMT can improve 
metabolic phenotypes, including median rate of glucose disappearance and insulin 
sensitivity among males with metabolic syndrome (P < 0.05), which is relevant in light of 
obesity-associated insulin resistance that can develop in T1D98,99. Thus, experimenting with 
FMT and other adjunct therapies in treating symptoms of AN and T1D may provide insight 
into how the gut microbiota contribute to disease pathology and prognosis.
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Synopsis
Anorexia nervosa has poor prognosis and treatment outcomes, and is influenced by 
genetic, metabolic, and psychological factors. Gut microbes interact with gut physiology 
to influence metabolism and neurology, although potential therapeutic benefits remain 
unknown. Type 1 diabetes is linked to anorexia through energy dysregulation, which in 
both disease states is related to the gut microbiota, disordered eating, and genetics.
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Key points
• Anorexia nervosa is highly refractory, and novel treatments are needed to 
improve prognosis.
• The gut microbiota is dysregulated in anorexia nervosa, and may be a new 
avenue for research in reducing discomfort during refeeding.
• Metabolism is often dysregulated in anorexia nervosa and type 1 diabetes, 
which share common genetic alterations, disordered eating patterns, and 
features of gut microbial dysbiosis.
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Figure 1: 
Factors that influence gut microbial composition, SCFA production, and diversity in 
anorexia nervosa.
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